Acrivon Therapeutics, Inc. (ACRV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Acrivon Therapeutics, Inc. (ACRV) Healthcare & Pipeline Overview

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary proteomics-based platform to develop targeted oncology medicines. Their approach focuses on identifying patient responders through companion diagnostics, potentially improving treatment outcomes in a competitive biotechnology landscape. The lead candidate, ACR-368, is currently in Phase 2 trials.

What Is the Investment Thesis for ACRV?

Acrivon Therapeutics presents a notable research candidate due to its innovative precision medicine platform and promising clinical pipeline. The company's AP3 platform differentiates it from traditional drug development approaches by enabling the identification of patient responders, potentially leading to higher clinical trial success rates and faster regulatory approvals. The ongoing Phase 2 trial of ACR-368 in multiple tumor types represents a significant near-term catalyst. Positive data from this trial could drive substantial value appreciation. However, the company's reliance on a single lead candidate and the inherent risks associated with clinical-stage drug development should be carefully considered. The market capitalization of $87.3M reflects both the potential upside and the risks involved.

Based on FMP financials and quantitative analysis

ACRV Key Highlights

Lead clinical candidate ACR-368 is in a potentially registrational Phase 2 trial across various tumor types.

• The company's Acrivon Predictive Precision Proteomics (AP3) platform enables the creation of drug-specific OncoSignature companion diagnostics.
• Acrivon's pipeline includes preclinical programs targeting WEE1 and PKMYT1, critical nodes in DNA damage response and cell cycle regulation.
• The company was incorporated in 2018 and is based in Watertown, Massachusetts.
• The company employs 75 people.

Who Are ACRV's Competitors?

ACRV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ACRV's Key Strengths?

Proprietary proteomics-based patient responder identification platform.

• Clinical-stage lead candidate ACR-368 with Phase 2 trial ongoing.
• Experienced management team.
• Focus on precision medicine and targeted therapies.

What Are ACRV's Weaknesses?

Reliance on a single lead candidate.

• Limited financial resources.
• Dependence on successful clinical trial outcomes.
• High attrition rate in drug development.

What Could Drive ACRV Stock Higher?

Data readout from the ongoing Phase 2 trial of ACR-368 across various tumor types.

• Initiation of clinical trials for preclinical pipeline programs targeting WEE1 and PKMYT1.
• Potential strategic partnerships with pharmaceutical companies.
• Potential out-licensing of Acrivon's OncoSignature companion diagnostics.

What Are the Key Risks for ACRV?

Financial-distress signal — its Altman Z-Score of -1.92 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-64.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Unfavorable results from the Phase 2 trial of ACR-368.
• Delays in regulatory approvals.
• Competition from other biotechnology and pharmaceutical companies.
• High attrition rate in drug development.
• Limited financial resources.

What Are the Growth Opportunities for ACRV?

• Growth opportunity 1: Expansion of ACR-368 into additional tumor types represents a significant growth opportunity for Acrivon. Positive data from the ongoing Phase 2 trial could support the initiation of new clinical trials in other cancer indications where CHK1 and CHK2 are relevant targets. This expansion could broaden the potential market for ACR-368 and drive revenue growth. The timeline for this expansion depends on the results of the current Phase 2 trial, with potential new trials initiating within the next 2-3 years. The market size for each new indication could range from hundreds of millions to billions of dollars.
• Growth opportunity 2: Advancing preclinical pipeline programs targeting WEE1 and PKMYT1 offers another avenue for growth. These programs address critical nodes in the DNA damage response and cell cycle regulation pathways, which are relevant to a wide range of cancers. Successful development of these programs could lead to new drug candidates and expand Acrivon's product portfolio. The timeline for these programs is longer-term, with potential clinical trials initiating in 3-5 years. The market size for each new drug candidate could be substantial, depending on the target and indication.
• Growth opportunity 3: Strategic partnerships with pharmaceutical companies could accelerate the development and commercialization of Acrivon's drug candidates. Collaborations could provide access to additional resources, expertise, and market reach. Potential partners could include companies with complementary technologies or those seeking to expand their oncology portfolios. The timing of such partnerships is uncertain, but they could occur at any stage of development. The financial terms of these partnerships could vary widely, but they could provide significant upfront payments, milestone payments, and royalties.
• Growth opportunity 4: Out-licensing of Acrivon's OncoSignature companion diagnostics could generate revenue and expand the reach of its precision medicine platform. These diagnostics could be used to identify patients who are most likely to respond to other companies' drugs, thereby improving treatment outcomes and reducing healthcare costs. Potential licensees could include pharmaceutical companies, diagnostic companies, and healthcare providers. The timing of such out-licensing agreements is uncertain, but they could occur in the near term. The financial terms of these agreements could include upfront payments, milestone payments, and royalties.
• Growth opportunity 5: Expansion into new geographic markets represents a longer-term growth opportunity for Acrivon. The company could seek to commercialize its drugs and diagnostics in regions outside of the United States, such as Europe and Asia. This expansion would require establishing local partnerships, navigating regulatory requirements, and building commercial infrastructure. The timeline for this expansion is uncertain, but it could occur within the next 5-10 years. The market size for each new geographic market could be substantial, depending on the prevalence of cancer and the availability of healthcare resources.

What Are ACRV's Competitive Advantages?

• Proprietary Acrivon Predictive Precision Proteomics (AP3) platform.
• Drug-specific OncoSignature companion diagnostics.
• Clinical-stage lead candidate ACR-368 with promising Phase 2 trial results.
• Experienced management team with expertise in drug development and precision medicine.

What Does ACRV Do?

Acrivon Therapeutics, Inc., founded in 2018 and based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through precision medicine. The company's core innovation lies in its Acrivon Predictive Precision Proteomics (AP3) platform, which enables the development of drug-specific OncoSignature companion diagnostics. These diagnostics are designed to identify patients whose tumors are most likely to respond to Acrivon's drug candidates, thereby increasing the probability of successful treatment outcomes. Acrivon's lead clinical candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, two key proteins involved in DNA damage response. ACR-368 is currently undergoing a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Beyond ACR-368, Acrivon is also advancing a preclinical pipeline targeting other critical nodes in the DNA damage response and cell cycle regulation pathways, including WEE1 and PKMYT1. By focusing on patient selection and targeted therapies, Acrivon aims to improve the efficacy and reduce the toxicity of cancer treatments.

What Products and Services Does ACRV Offer?

• Develop oncology medicines for patients with tumors predicted to be sensitive to specific medicines.
• Utilize a proteomics-based patient responder identification platform.
• Create drug-specific OncoSignature companion diagnostics.
• Identify patients who are most likely to benefit from their drug candidates.
• Develop small molecule inhibitors targeting CHK1 and CHK2.
• Advance preclinical pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways.

How Does ACRV Make Money?

• Develop proprietary OncoSignature companion diagnostics to identify patient responders.
• Out-license OncoSignature companion diagnostics.
• Develop and commercialize oncology medicines, such as ACR-368.
• Generate revenue through strategic partnerships with pharmaceutical companies.

What Industry Does ACRV Operate In?

The biotechnology industry is characterized by high innovation, intense competition, and significant regulatory hurdles. Precision medicine, which aims to tailor treatments to individual patients based on their genetic and molecular profiles, is a rapidly growing area within the industry. Acrivon's focus on proteomics-based patient responder identification aligns with this trend. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing targeted cancer therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies. The overall oncology market is projected to continue growing, driven by an aging population and increasing cancer incidence rates.

Who Are ACRV's Key Customers?

• Patients with cancer who are likely to respond to Acrivon's medicines.
• Pharmaceutical companies seeking to develop and commercialize targeted cancer therapies.
• Diagnostic companies seeking to expand their portfolio of companion diagnostics.
• Healthcare providers seeking to improve treatment outcomes and reduce healthcare costs.

Company Profile

Acrivon Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Peter Blume-Jensen. ACRV has traded publicly since 2022.

Acrivon Therapeutics, Inc. Financial Trajectory

Acrivon Therapeutics, Inc. (ACRV) reported $0 in revenue for Jun 2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $18.0M, with diluted EPS of $-0.43. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ACRV averaged $-0.47 in diluted EPS.

How Acrivon Therapeutics, Inc. Is Valued

Acrivon Therapeutics, Inc. carries a market capitalization of $87.3M, placing it in the micro-cap category. Relative to its peer group, ACRV's quantitative score of 29/100 is below the peer average of 77/100.

Return on equity for Acrivon Therapeutics, Inc. stands at -64.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -71.7%, showing how much profit it generates from its asset base. A current ratio of 8.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -124.7%, the inverse of the P/E and a quick read on earnings relative to price.

Acrivon Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.92 places it in the distress zone, a signal of elevated financial risk.

Acrivon Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.7% above estimates on average.

Wall Street analysts project Acrivon Therapeutics, Inc. revenue of about $1.5M for fiscal 2026, with EPS near $-1.91. The estimate reflects 5 contributing analysts.

Over the past six months, Acrivon Therapeutics, Inc. insiders filed 42 SEC Form 4 transactions — 17 sales and 25 purchases. On net that is roughly 4.7M shares acquired (about $7.4M) — insiders putting money in tends to read as conviction.

ACRV Financials

ACRV Latest News

ACRV Analyst Consensus

ACRV MoonshotScore

Common Questions About ACRV (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources